Cetuximab plus chemotherpay and/or radiotherapy in the treatment of refractory metastatic cancer
WANG Ruo-zheng,CHEN Zhi-qiang,WU Pu-er,WANG Duo-ming,LIU Kai (Department of Radiation Oncology,Tumor Hospital Affiliated to Xinjiang Medical University,Urumuqi Xinjiang,8300011,China)
Background and purpose:Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We explored the efficacy and toxicity of cetuximab plus chemotherapy and/or radiotherapy in the refractory metastatic patients with head and neck cancer and colorectal cancer. Methods:Six patients of refractory metastatic cancer were treated with cetuximab in combination with radiotherapy and chemotherapy. All patients were confirmed by histological diagnosis. Three patients were diagnosed as refractory metastatic head and neck cancer and others as refractory metastatic colorectal cancer. The patients of head and neck cancer were treated with docetaxel and radiotherapy in combination with cetuximab. The patients of colorectal cancer were treated with irinotecan and capecitabine. Cetuximab was given at an initial dose of 400 mg/m2,followed by weekly infusions of 250 mg/m2.Results:2 patients with PR,3 patients with SD and 1 patient with PD. the median time of tumor to progression(TTP) was 18.5 weeks. The major toxicities were acne-like rash and diarrhea.Conclusions:Cetrximab in combination with chemotherapy and/or radiotherapy has clinically significant activity in patients with refractory metastatic cancer. The toxicity except rash was not more frequent among the patients receiving cetuximab in combination with chemotherapy and/or radiotherapy than chemotherapy and/or radiotherapy alone.
【CateGory Index】： R730.5